Enterprise Value
160M
Cash
17.97M
Avg Qtr Burn
-9.053M
Short % of Float
5.06%
Insider Ownership
29.09%
Institutional Own.
12.08%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Belapectin (GR-MD-02) Details Non-alcoholic steatohepatitis | Phase 2/3 Data readout | |
Belapectin (GR-MD-02) + keytruda Details Head and neck cancer, Head and neck squamous cell carcinoma | Phase 2 Initiation | |
Belapectin (GR-MD-02) Details Psoriasis | Failed Discontinued |